Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 15/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | MITF | O75030 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25755170 | 0.79 | KMT2A (0.38) | GPR139NPC1MITFALDH1A1MAPT | |
| SCHEMBL25755264 | 0.78 | NPC1 (0.36) | GPR139NPC1MITFALDH1A1MAPT | |
| SCHEMBL25755463 | 0.74 | ALDH1A1 (0.35) | GPR139ALDH1A1 | |
| SCHEMBL25755506 | 0.74 | ALDH1A1 (0.36) | GPR139NPC1MITFALDH1A1MAPT | |
| SCHEMBL22146264 | 0.73 | NPC1 (0.33) | GPR139NPC1MITFALDH1A1MAPT | |
| SCHEMBL18955984 | 0.73 | NPC1 (0.44) | GPR139NPC1MITFALDH1A1MAPT | |
| SCHEMBL25755572 | 0.73 | GPR139 (0.32) | GPR139 | |
| SCHEMBL27199398 | 0.72 | PTGS2 (0.34) | GPR139NPC1MITFALDH1A1MAPT | |
| SCHEMBL25755354 | 0.71 | GPR139 (0.32) | GPR139 | |
| SCHEMBL30508823 | 0.69 | ALDH1A1 (0.33) | NPC1MITFALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | GPR139 4403/4885NPC1 4269/4885MITF 1173/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | GPR139 4403/4885NPC1 4269/4885MITF 1173/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | GPR139 4403/4885NPC1 4269/4885MITF 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.